News Column

Reports from Institute of Biomaterials Describe Recent Advances in Drug Delivery Systems (In situ covalently cross-linked PEG hydrogel for ocular...

August 6, 2014



Reports from Institute of Biomaterials Describe Recent Advances in Drug Delivery Systems (In situ covalently cross-linked PEG hydrogel for ocular drug delivery applications)

By a News Reporter-Staff News Editor at Biotech Week -- Current study results on Drugs and Therapies have been published. According to news reporting originating in Wenzhou, People's Republic of China, by NewsRx journalists, research stated, "Avastin has been clinically proved to be effective in the treatment of intraocular neovascularization diseases. However, the short half-life of Avastin need frequent administration to maintain its therapeutic efficiency."

The news reporters obtained a quote from the research from the Institute of Biomaterials, "In this paper, we attempted to develop an in situ PEG hydrogels with great biocompatibility for sustained release of Avastin to inhibit the corneal neovascularization. PEG hydrogels was formed via thiol-maleimide reaction using 4-arm PEG-Mal and 4-arm PEG-SH. The transparent hydrogel was rapidly formed under physiological conditions. By varying the concentration of 4-arm PEG-SH, PEG hydrogel with different gelling time, pore size, swelling ratio and mechanical property could be obtained. In vitro cytotoxicity indicated that the developed PEG hydrogel had no apparent cytotoxicity on L-929 cells after 7 days of incubation. In vitro release study showed the encapsulated Avastin was sustained release from PEG hydrogels within a period of 14 days study. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) analysis further confirmed that the released Avastin did not undergo apparent hydrolysis within 14 days."

According to the news reporters, the research concluded: "As a conclusion, we could conclude that the developed PEG hydrogels as an injectable hydrogels might be suitable for extended Avastin release to treat the corneal neovascularization."

For more information on this research see: In situ covalently cross-linked PEG hydrogel for ocular drug delivery applications. International Journal of Pharmaceutics, 2014;470(1-2):151-157. International Journal of Pharmaceutics can be contacted at: Elsevier Science Bv, PO Box 211, 1000 Ae Amsterdam, Netherlands. (Elsevier - www.elsevier.com; International Journal of Pharmaceutics - www.elsevier.com/wps/product/cws_home/505513)

Our news correspondents report that additional information may be obtained by contacting J. Yu, Wenzhou Inst Biomat & Engn, Wenzhou 325035, People's Republic of China. Additional authors for this research include X. Xu, F.L. Yao, Z.C. Luo, L. Jin, B.B. Xie, S. Shi, H.X. Ma, X.Y. Li and H. Chen (see also Drugs and Therapies).

Keywords for this news article include: Asia, Wenzhou, Alcohols, Hydrogel, Organic Chemicals, Neovascularization, Drugs and Therapies, Polyethylene Glycols, Drug Delivery Systems, People's Republic of China

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Biotech Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters